Tag Archives: CRME

Top 10 Medical Stocks For 2018

Organovo Holdings Inc. (NASDAQ: ONVO) shares saw a handy gain on Tuesday after the bio-printer announced that it received a strong consumer response from its second tissue service. Specifically, the ExVive Human Kidney Tissue launched in September, which uses Organovos 3D bio-printed kidney tissue to study the effects of drug exposure through toxicology panels and transporter studies.

The company already has multiple commercial orders from several customers, including with two global, top 25 pharmaceutical companies.

For some background: Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.

Top 10 Medical Stocks For 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

  • [By kiplinger]

     52-week high: $18.93 


    52-week low: $11.01 

    Annual revenues: $492.9 million 

    Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

Top 10 Medical Stocks For 2018: Apartment Investment and Management Company(AIV)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Scripps Networks Interactive (SNI) sunk to the bottom of the S&P 500–narrowly beating out Apartment Investment and Management (AIV)–as the parent company of the Food Network and other channels gave back a chunk of its post-elections gains.

  • [By Ben Levisohn]

    Apartment Investment & Management (AIV) tumbled today, as the weakness in real-estate investment trusts following Donald Trump’s surprise election continued today. It was the second-biggest loser in the S&P 500 today.

    Getty Images

    Shares of Apartment Investment & Management dropped 4.1% to $41.03 today, while the Real Estate SPDR Dow Jones REIT ETF (RWR) fell 1.1% to $90.03. The S&P 500 rose rose 0.8% to 2,180.39.

    In a note released yesterday, Raymond James analyst Buck Horne and team cut their price target on Apartment Investment & Management to $50 from $50, even as they maintained their Strong Buy rating. They explain why:

    Prefacing our comment qualifying the significant economic uncertainties that have arisen post Tuesdays election, we are maintaining our Strong Buy rating onApartment Investment & Management shares while slightly adjusting our target price (to $50 from $52) and net-asset-value estimate (down $1 to $48.51/share). These adjustments are solely to reflect slightly more conservatism in our cap rate assumptions following the post-election interest rate shifts. We continue to find Apartment Investment & Managements risk/reward profile compelling in this environment as its diversified class B-priced portfolio should prove more resilient to supply pressures and benefit from the growing shortage of affordable workforce housing. In an inflationary environment with potentially declining housing affordability, we are particularly attracted to Aimcos price points, demographics, and balance sheet full of long-dated, non-recourse, fixed rate leverage.

    Apartment Investment & Management reported net income of $67 million on sales of $978 million in 2015.

Top 10 Medical Stocks For 2018: region(DGLD)

Advisors’ Opinion:

  • [By Jim Robertson]

    The VelocityShares 3x Inverse Gold ETN (NASDAQ: DGLD) seeks to provideshort exposure to three times (3x) the daily performance of theS&P GSCI Gold Index. As with UGLD, DGLD would be doing this viafutures contracts.

Top 10 Medical Stocks For 2018: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

Top 10 Medical Stocks For 2018: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

    Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

Top 10 Medical Stocks For 2018: AltaGas Ltd. (ATGFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    AltaGas (OTCPK:ATGFF) recently announced that it’s going to acquire WGL Holdings (NYSE:WGL). This article will examine the financial side of the transaction. A number of Seeking Alpha authors have written articles on the merger as well, and I suggest that you read them.

  • [By SEEKINGALPHA.COM]

    Regulators in California are behind a new business of providing utility-scale back-up battery storage at power generating facilities. Canadian-based AltaGas (OTCPK:ATGFF) recently announced a 10-year Energy Storage Resource Adequacy Purchase Agreement with Southern California Edison SCE, a subsidiary of Edison International (NYSE:EIX). A recap of the scope of the contract is described below, from ATGFF’s press release:

Top 10 Medical Stocks For 2018: YPF Sociedad Anonima(YPF)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Knighthead Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Knighthead+Capital+Management%2C+LLC

    These are the top 5 holdings of Knighthead Capital Management, LLCSPDR S&P 500 (SPY) – 1,500,000 shares, 57.03% of the total portfolio. Spirit Realty Capital Inc (SRC) – 9,113,000 shares, 11.82% of the total portfolio. New PositionYPF SA (YPF) – 2,153,795 shares, 7.26% of the total portfolio. Shares reduced by 1.5%TerraForm Global Inc (GLBL) – 9,200,000 shares, 6.61% of the total portfolio. EQT Corp (EQT) – 597,300 shares, 5.9% of the total p

Top 10 Medical Stocks For 2018: Clarke(t)

Advisors’ Opinion:

  • [By JJ Kinahan]

    Shares of AT&T Inc. (NYSE: T) were moderately lower while shares of Time Warner Inc (NYSE: TWX) headed to the upside in early trading today. Late yesterday, the Department of Justice (DoJ) surprised market observers by filing an antitrust lawsuit to block T’s $85.4 billion takeover of TWX. In the complaint, DoJ said the merger would harm competition, stifle innovation and drive up prices.

  • [By Laurie Kulikowski]

    Net operating cash flow has increased to $10,797.00 million or 23.76% when compared to the same quarter last year. In addition, AT&T INC has also modestly surpassed the industry average cash flow growth rate of 16.21%.

    The gross profit margin for AT&T INC is rather high; currently it is at 55.43%. Regardless of T’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.65% trails the industry average.

     

  • [By Chris Lange]

    24/7 Wall St. took a peek at plans from Verizon Communications Inc. (NYSE: VZ), AT&T Inc. (NYSE: T), T-Mobile US Inc. (NASDAQ: TMUS) and Sprint Corp. (NYSE: S). We have also provided some of the key highlights from each plan. In a separate post we looked at which companies offer the best service.

  • [By WWW.MONEYSHOW.COM]

    With a dividend yield of 4.8%, AT&T (T) will continue to be an attractive income investment whether or not the merger with Time Warner (TWX) happens. AT&T recently completed other deals that have increased earnings and strengthened dividend safety.

Top 10 Medical Stocks For 2018: New Residential Investment Corp.(NRZ)

Advisors’ Opinion:

  • [By ]

    New Residential (NYSE: NRZ) is a U.S.-based REIT that specializes in managing investments in residential real estate. With a market cap of $5.5 billion, NRZ is one of the largest REITs in the United States, so this is no fly-by-night company. NRZ offers one of the best dividends in the industry. The trust made four dividend payments in 2017 totaling $1.94. That gives shares a current yield of 11.3%, more than a 400% premium to the S&P 500’s average 2.0% yield.

  • [By Lisa Levin]

    Ocwen Financial Corp (NYSE: OCN) shares were also up, gaining 42 percent to $3.25. New Residential Investment Corp (NYSE: NRZ) revealed it owned some servicing rights to the troubled Ocwen Financial. During today's conference call, New Residential’s executive suggested the company will pay $425 million for Mortgage Servicing Rights to Ocwen.

  • [By Sean Williams]

    Today’s lawsuit has spilled over to the company’s peers as well. New Residential Investment Corp. (NYSE:NRZ), which invests in excess mortgage servicing rights (MSRs), wound up falling as much as 13% during the day’s trading session. Ocwen is one of the three companies mentioned as being one of the primary servicers in New Residential Investment’s MSRs, according to its 10-K. If mortgage owners or bondholders terminate Ocwen as the servicer, the excess MSRs tied to Ocwen could lose some or all of their value.Altisource Portfolio Solutions S.A.(NASDAQ: ASPS)fell 42%.

  • [By Chris Dier-Scalise]

    Thge Vetr crowd upgraded its rating for New Residential Investment Corp (NYSE: NRZ) on Friday from the company's previous standing at 3 stars (Hold), issued 10 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Top 10 Medical Stocks For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

top 50 stocks to buy

Gold prices were little-changed in early in European trading after the bullion touched a five-month high in Asia as investors piled into safe-haven assets around the world amid rising geopolitical tensions. 

Spot gold was marked 0.01% lower at $1,274.30 per ounce in early London trading after reaching a five-month high of $1,279.80 in Asia dealing amid a retreat from risk assets such as stocks and corporate bonds. 

Gold mining stocks were also lower, with Randgold Resources (GOLD) falling around 1.5% and Fresnillo Plc (FNLPF) slipping 0.85%. Randgold’s 10.66% advance over the past three months, however, has nearly doubled that of spot gold prices while Fresnillo’s 15.82% rise is nearly three times higher than the bullion’s gain over the same period. 

top 50 stocks to buy: Constellation Brands Inc(STZ)

Advisors’ Opinion:

  • [By Ben Levisohn]

    As the stock market has rallied sinceDonald Trump’s election in November, Constellation Brands (STZ) has basically sat it out, weighed down by concerns that a new tax plan would hurt the multinational alcoholic beverage company’s profits.

  • [By WWW.THESTREET.COM]

    Then on Thursday, Constellation Brands (STZ) reports, and as we learned yesterday, this is Cramer’s favorite liquor stock. Also on Thursday, earnings from Nike (NKE) , a battleground Cramer said he’s steering clear of, and Micron Technology (MU) , which will likely fall no matter how good its quarter.

  • [By ]

    Earlier this quarter, I told you how alcohol distributor Constellation Brands Inc. (NYSE:STZ) acquired a 10% stake in Canadian medical marijuana firm Canopy Growth Corp. (TSE:WEED). A major alcohol distributor buying a marijuana company would have been unfathomable just a few years ago. But with legalization gaining steam nationwide, this deal is shaping up to be one of many to come in the industry.

  • [By Casey Wilson]

    Constellation Brands Inc. (NYSE: STZ), which owns popular beer brands like Corona, is the latest company to realize the profit potential of the legal marijuana industry.

  • [By Craig Jones]

    Najarian also noticed big upside call options buying in Constellation Brands, Inc. (NYSE: STZ). Around 5,000 contracts of the January 240 calls were traded and he decided to follow the trade. He added that he also likes Wal-Mart Stores Inc (NYSE: WMT) for upside calls buying.

top 50 stocks to buy: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

top 50 stocks to buy: Deltic Timber Corporation(DEL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

top 50 stocks to buy: Rigel Pharmaceuticals Inc.(RIGL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares dropped 22 percent to $2.52 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint.

top 50 stocks to buy: Diplomat Pharmacy, Inc.(DPLO)

Advisors’ Opinion:

  • [By Paul Ausick]

    Diplomat Pharmacy Inc. (NYSE: DPLO) dropped 7.4% Monday, posting a new 52-week low of $12.25 after closing at $13.23 on Friday. The stock’s 52-week high is $38.94. The specialty pharmacy company said this morning that revenues and adjusted EBITDA for 2016 will come in at or near the low end of the company’s previously announced range.

  • [By Lisa Levin]

    Shares of Diplomat Pharmacy Inc (NYSE: DPLO) were down 23 percent to $14.71. Diplomat Pharmacy agreed to buy LDI Integrated Pharmacy Services. Baird downgraded Diplomat Pharmacy from Outperform to Neutral.

Top Heal Care Stocks To Invest In 2018

Related EWP Maybe Some Relief For The Spain ETF Politics Prove Problematic For The Spain ETF

Relatively speaking, the iShares MSCI Spain Capped ETF (NYSE: EWP) has not been that bad compared to other single-country exchange-traded funds tracking PIIGS economies. Year-to-date, EWP is down 3.8 percent, a loss that is only half as bad as the equivalent Ireland ETF and far superior to the average loss of 14.5 percent for the comparable Greece and Italy ETFs.

As is the case with other members of the PIIGS group, there have been lingering concerns about the health of Spanish banks. However, there are signs banks in the eurozone's fourth largest economy are regaining some health. The health of Spanish banks is of particular importance to EWP because the Spain ETF, as is the case with so many single-country funds, devotes a significant percentage of its weight to financial services names.

Top Heal Care Stocks To Invest In 2018: Rubicon Technology, Inc.(RBCN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap LED semiconductor stockRubicon Technology (NASDAQ: RBCN):

    Rubicon Technology isn’t going to be a monster-sized winner for us, even if things go perfectly. About the best downside target we could hope for is the $0.60 area, where the stock was launched into an unsustainable uptrend a week ago. But, it’s a high-odds trade we can’t pass up. Yesterday’s doji bar after a big rally was a warning sign that we were transitioning into a net-selling environment. Today’s sharp pullback confirms we’re moving into that bearish mode.

Top Heal Care Stocks To Invest In 2018: Rovi Corporation(ROVI)

Advisors’ Opinion:

  • [By Emily Stewart]

    Rovi (ROVI) is a new second-quarter acquisition for Soros, who as of the end of the period owns 4.1 million shares worth $63.6 million.

    Rovi is engaged in the discovery, delivery, display and monetization of digital entertainment by providing a broad set of integrated solutions. It has a $1.8 billion market cap. 

Top Heal Care Stocks To Invest In 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top Heal Care Stocks To Invest In 2018: Volkswagen Aktiengesellschaft (VLKAY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Welcome to the July 2017 edition of Electric Vehicle (EV) company news. In many ways, I think July 2017 will be remembered as a major turning point in EV history – with Model 3 production underway, the British and French governments declaring ICE bans, Volkswagen (OTCPK:VLKAY), Big Oil and the IMF acknowledging EVs are the way of the future. What a monumental month for EVs – matched with near-record global sales.

  • [By SEEKINGALPHA.COM]

    Navistar International Corporation (NYSE:NAV) has had a wild ride over the past year, going from a $38.05 per share two years ago down to $5.78 in one year, and recovering back to around $32 over the past year, with a notable double in the past four months on news of the proposed alliance with Volkswagen Truck & Bus (“VW”), a wholly owned subsidiary of Volkswagen AG (OTCPK:VLKAY).

  • [By SEEKINGALPHA.COM]

    2019 going into 2020 is when autonomous cars start to ramp. Let’s look at some of the industry news bits:

    NuTonomy to expand self-driving taxi service to 10 cities around the world by 2020 (Source: Yahoo News) Delphi (NYSE:DLPH) and Mobileye to provide off-the-shelf self-driving system by 2019 (Source: TheVerge) Volkswagen (OTCPK:VLKAY) expects first self-driving cars on the market by 2019 (Source: Focus) Ford’s head of product development: autonomous vehicle on the market by 2020 (Source: Auto News) Baidu’s (NASDAQ:BIDU) chief scientist expects a large number of self-driving cars on the road by 2019 (Source: Quora) First autonomous Toyota to be available in 2020 (Source: Wired.com) Nissan (OTCPK:NSANY) to provide fully autonomous vehicles by 2020 (Source: Nissan Motors) Sergey Brin plans to have Google (NASDAQ:GOOG) (NASDAQ:GOOGL) driverless car in the market by 2018 (Source: Driverless car market watch)

    There is a clear trend here. Most players in the space plan on really ramping after 2019 going into 2020. Let’s assume Tesla can hit its 500k goal after 2018, in 2019, it would have 1.2mm autonomous capable cars on the road vs. a 4.4mm installed base or 27% of the global base. Then, in 2020, Tesla would have 1.7mm autonomous capable cars vs. a base of 10mm or 17% of the global base. You may think that Tesla is starting to look less impressive. That’s not really the case when you factor in that automakers make about 75mm cars a year globally. Tesla will still have a larger percentage of the autonomous fleet in 2020 than Toyota’s percentage of the entire global automotive fleet at around 15%. With that being said, I do think 2019-2020 is when Tesla’s chokehold on the autonomous vehicle fleet will start to come under pressure. Tesla needs to figure out how to ramp to Ford, Nissan or Honda (NYSE:HMC) type production levels to maintain its dominance. Is that even possible?

  • [By John Rosevear]

    In terms of production, Audi’s electric-vehicle effort is supported by corporate parent Volkswagens (NASDAQOTH:VLKAY) aggressive, big-budget move toward electric vehicles. Nearly all of VW’s brands are known to have long-range electric vehicles under development. Audi’s economies of scale (via VW) could well eclipse Tesla’s by early next decade.

  • [By SEEKINGALPHA.COM]

    The company’s auto catalyst business has been roughly cut in half over the last five years due to a mix of Chinese export restrictions, cheaper products from Asian competitors, and IP infringement. Luxfer is doing what it can, including suing infringers and working on next-gen products, but I think it is too bullish to expect the company to regain all that it lost. Catalysts for the passenger diesel market are an interesting opportunity, but it increasingly seems that, in the wake of the Volkswagen (OTCPK:VLKAY) scandal, auto OEMs are tired of messing around with “clean diesel” and instead are moving quickly toward hybrid and electric vehicle technologies.

  • [By SEEKINGALPHA.COM]

    Last decennium, the popularity of both French Peugeot and Citro毛n has lost traction against that of German car manufacturers. PSA experienced declining sales, while German car manufacturers Volkswagen (OTCPK:VLKAY), BMW (OTCPK:BMWYY) and Daimler (OTCPK:DDAIF) have been stacking up sales records year after year over the last 6 years.

Top Heal Care Stocks To Invest In 2018: Cliffs Natural Resources Inc.(CLF)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

  • [By Lisa Levin]

    Basic materials shares rose by 0.74 percent in the US market on Friday. Top gainers in the sector included AK Steel Holding Corporation (NYSE: AKS), Cliffs Natural Resources Inc (NYSE: CLF), and United States Steel Corporation (NYSE: X).

  • [By Javier Hasse]

    Steel stocks are spiking on Monday afternoon, with AK Steel Holding Corporation (NYSE: AKS) up almost 7.5 percent, United States Steel Corporation (NYSE: X) up about 6.4 percent, Cliffs Natural Resources Inc (NYSE: CLF) up more than 1 percent and Mechel PAO (ADR) (NYSE: MTL) up 16.8 percent. The stocks are not being helped by a few analyst upgrades (although, surely not hurt by them), but seem to be mostly rallying on the back of Donald Trump’s election as president of the United States.

  • [By Lisa Levin]

    Basic materials sector was the top gainer in the US market on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), Cliffs Natural Resources Inc (NYSE: CLF), and Olympic Steel, Inc. (NASDAQ: ZEUS).

Hot Blue Chip Stocks For 2018

This is part of a series of stories that comprise TheStreet’s Blue Chip Studio, which will illuminate issues related to corporate board performance, activism, dealmakers and personalities revealed by analysis of data generated by BoardEx, a business unit of TheStreet.

BlackRock (BLK), the world’s largest asset manager, said it will be putting pressure on companies to address boardroom diversity as part of a series of initiatives for 2017-2018 that the company’s 30-member Investment Stewardship team will discuss with portfolio companies.

The New York-based firm, with $5.1 trillion under management, said board composition, effectiveness, and accountability remain a top priority, and that it plans to engage companies in a constructive manner.

“More specifically, over the coming year, we will engage companies to better understand their progress on improving gender balance in the boardroom,” the firm said on its website on Monday. “Diverse boards, including but not limited to diversity of expertise, experience, age, race and gender, make better decisions.”

Hot Blue Chip Stocks For 2018: Dynavax Technologies Corporation(DVAX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Dynavax Technologies Corporation (NASDAQ: DVAX) shares were also up, gaining 17 percent to $6.88 after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.

  • [By Lisa Levin]

    Dynavax Technologies Corporation (NASDAQ: DVAX) shares shot up 73 percent to $15.99 as the company announced that the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration voted 12-1 in support of the company’s Hepatitis B vaccine, HEPLISAV-B. RBC Capital upgraded Dynavax from Sector Perform to Outperform.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By WWW.KIPLINGER.COM]

    Add Dynavax Technologies Corp. (DVAX) to the list of biotech stocks to watch on or a little before Dec. 15. Thats when the company is going to get a yay or nay from the Food & Drug Administration about Heplisav-B as a treatment for hepatitis B in people with type 2 diabetes

Hot Blue Chip Stocks For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Hot Blue Chip Stocks For 2018: Cotiviti Holdings, Inc. (COTV)

Advisors’ Opinion:

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

Hot Blue Chip Stocks For 2018: Limelight Networks Inc.(LLNW)

Advisors’ Opinion:

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)